On September 8, Roivant Sciences Ltd. rose 14.2% in regular trading, trading at $40.0/share, with turnover of $39.47 million. The rally was driven by the announcement that its Pulmovant unit's inhaled sGC activator Mosliciguat achieved positive results in the Phase 2 PHocus study in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The study met both its primary and secondary endpoints, demonstrating a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at week 16, a 35.2-meter improvement in six-minute walk distance, and a 53.2% decline in NT-proBNP. In a prespecified exploratory analysis, the placebo-adjusted improvement in six-minute walk distance increased to 52.7 meters at week 24, while the NT-proBNP reduction reached 75.9%. The drug was well tolerated with a favorable safety profile, and treatment benefits continued to improve through week 24. The company simultaneously disclosed the initiation of the Phrontier Phase 3 trial, advancing Mosliciguat toward the registration stage. PH-ILD has long lacked effective therapies, making these results a potential breakthrough for the field.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)